StemCyte Management Team
Our StemCyte executive management team is comprised of Physicians, Scientists and strong business leaders with a vast and varied array of experience in the medical products and services industry. This type of leadership makes StemCyte the gold standard in cord blood banking and a company you can trust.
Kenneth J. Giacin, MBA, MS
Chairman of the Board of Directors
Ken Giacin joined StemCyte in 2003, bringing world-class leadership to guide the company's growth through new investments and technological affiliations. In addition to being the Chairman of StemCyte, Inc. he also holds the Chairmanship of StemCyte Taiwan and the StemCyte India Joint Venture. Prior to joining StemCyte, Ken had an outstanding and diverse career with Johnson & Johnson that spanned almost 26 years. His last assignment was Senior Vice President of Independence Technology, L.L.C., a Johnson & Johnson Company, which he started, that is dedicated to providing innovative products to people with disabilities and was responsible for all aspects of managing new business opportunities worldwide, a key element in building a global franchise within Johnson & Johnson. He held this position from 2000 to his 2003. From 1995 to 2000 he was General Manager of Independence Technology and served as a member of the Global Management Board throughout.
Ken served Johnson & Johnson in a series of assignments from 1974 to 1991. Beginning in Engineering and Operations with the Domestic Operating Company, he progressed through responsibilities in Operations, Marketing and Business Development and served on the Management Boards of the Baby Products Company as well as Consumer Products, Inc. as Vice President, Business Development.
From 1991 until his return to J&J in 1995, Ken was a Corporate Officer and Vice President, Worldwide Business Development for the Church & Dwight Company reporting to the Chairman. He was responsible for developing brand value and business for the Arm & Hammer Brand on a worldwide basis. In 1994, he added research and development responsibilities as Vice President, Business Development and Technology.
Prior to joining Johnson & Johnson, Ken served with the United States Navy as a carrier pilot and remained actively involved in aviation and non aviation command assignments with the Naval Reserve until his retirement in 1999 with the rank of Captain. He holds a Bachelors of Science, Masters of Science and an MBA, all from Rutgers University.
Ken has also served on a number of Boards and Advisory Panels including
-Board member of Cerebral Palsy of New Jersey
-Advisory Board of the Human Engineering Research Laboratory of the University of Pittsburgh.
-Industrial Advisory Committee to Rutgers University
- Advisory Board of the National Institute for Child Health and Development (NIH)
- Advisory Board of the Pan Pacific Symposium for Stem Cell Research
Jonas Wang, Ph.D.
Jonas Wang joined StemCyte in 2009. Prior to joining StemCyte, he was a Partner of Sycamore Management Corporation in Princeton. Mr. Wang focuses on life sciences and biotechnology investments, and prior to joining Sycamore in 2001, he was Vice President of Research and Technology at Johnson & Johnson ("J&J") Consumer Products and a Corporate Director of J&J Drug Delivery Technology Resource Center where he was responsible for new product technology, patent strategy, competitive intelligence, and new measurement methodology for skin and hair care franchise. Prior to joining J&J, Mr. Wang was an Associate Director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co. He has over 30 years of experience in pharmaceutical R&D management and business development. He was also a member of J&J Consumer Product Worldwide Licensing and Acquisition Committee and was the key driver for several major acquisitions. He has published extensively in drug delivery technology and received several awards in his field, including the Johnson Medal, the highest technical achievement award at J&J, for one of his inventions, an anti-wrinkle cream. Mr. Wang received the Distinguished Alumni awards from the National Defense Medical Center in Taiwan, Republic of China, and also from the University of Iowa. During his career with J&J, he developed more than 10 core technologies and filed more than 30 business-related patents. He received a Ph.D. in Physical Pharmacy from University of Iowa and Pharmacy degree from National Defense Medical Center in Taiwan, Republic of China.
President, North America Commercial Operations
Calvin Cole leads the StemCyte North America initiatives and strategic business development across the organization with a focus on developing external staff. His 20+ years of executive management and planning experience lends stellar guidance for StemCyte as it continues a period of unprecedented growth. He is also responsible for leveraging the StemCyte Brand to help define the competitive advantages for its Private Banking business. Prior to joining StemCyte, Calvin was Vice President for industry leader Hoveround Power Wheelchairs. While there, he was responsible for product marketing, strategic planning, new product planning, business development and Government Relations. He has also spent the past 15+ years lobbying Washington on issues in favor of consumers for the Home Medical Equipment industry. Calvin served honorably in the United States Army where his extensive military planning and strategic training has guided his prolific career as a senior executive in the healthcare industry.
Prof. Wise Young, M.D., Ph.D.
Chief Science & Medical Advisor
Dr. Wise Young, Richard H. Shindell Distinguished Chair in Neuroscience and Founding Director, W.M. Keck Center for Collaborative Neuroscience at Rutgers, The State University of New Jersey, is one of the world's most outstanding neuroscientists and a foremost leader in spinal cord injury research. With a B.A. from Reed College, a Ph.D. from University of Iowa, an M.D. from Stanford University and a Surgery Internship at New York University (NYU) and Bellevue Medical Center, he became Director of Neurosurgery Research at NYU. He was a part of the team which discovered and established high-dose methypredisolone (MP) as the first effective therapy for spinal cord injuries. The team also played a major role in Andy Blight's signal work on 4-aminopyridine (4-AP) which shows significant promise for increasing nerve conductivity. His pioneering standardized rat spinal cord injury model is used worldwide for testing therapies. He was the founder and editor-in-chief of the Journal of Neurotrauma, organizer of National and International Neurotrauma Societies, member of the Advisory Committees for the NIH, the National Academy of Sciences, NICHD and many spinal cord injury organizations. He has appeared as a guest on "20/20", "48 Hours", "Today", "Eye to Eye", Fox News and CNN. His work has been featured in a Life magazine special edition, in USA Today, and in numerous news, talk and print presentations worldwide. His honors include: NIH Jacob Javits Neuroscience Award (1985-1992), Wakeman Award (1991), Tall Texan of the Year Award (1997), "Cure" Award (1998), Trustees Award for Excellence in Research (2001), 2002 Asian American Achievement Award, Douglass Medal for work with the advancement of young women in the sciences (2003), and Elizabeth M. Boggs Award for service to the disability community (2004). In August 2001, TIME Magazine named Dr. Young as 'America's Best' in the field of spinal cord injury research.· In 2005 he was the first researcher elected to the Spinal Cord Injury Hall of Fame. In 2006, Dr. Young received The Hope Award – A Salute to Research Innovation, the New Jersey Educator of the Year Award, and the Caring Heart Award. When the Richard H. Shindell Chair in Neuroscience was established at Rutgers University in 2006, Dr. Young was named as the first person to hold that chair.·In 2007 the Motolinsky Foundation named Wise Young as the recipient of their Distinguished Citizen Award. Dr. Young also serves as Chairman of the Advanced Therapeutics and Clinical Studies Committee.
Professor Lawrence D. Petz, M.D.
Chief Medical Officer, StemCyte , Emeritus Professor of Pathology and Laboratory Medicine Former Director of Transfusion Medicine, UCLA Medical Center Los Angeles, California
Dr. Lawrence Petz joined StemCyte after serving as Director of Transfusion Medicine and Professor of Pathology & Laboratory Medicine at UCLA Medical Center. Prior to UCLA, Dr. Petz was Chairman of the Division of Medicine, Section Head of Hematology, and Director of the Department of Clinical and Experimental Immunology at the City of Hope National Medical Center. Dr. Petz is the author and editor of several well-known, authoritative textbooks, including the first bone marrow stem cell transplant textbook, Clinical Bone Marrow Transplantation (1983), all three editions of the widely used blood bank textbook, Clinical Practice of Transfusion Medicine, and the co-author of Immune Hemolytic Anemias, now in its second edition. As a pre-eminent authority in transfusion medicine and transplantation, Dr. Petz has authored and edited hundreds of publications, book chapters, and reviews. He has published in the New England Journal of Medicine, JAMA, Lancet, Annals of Internal Medicine, Transfusion Medicine, Transfusion, Transplantation, Bone Marrow Transplant, Journal of Clinical Investigation, Postgraduate Medicine, Transfusion Medicine, Medicine, Journal of Immunology, Blood, British Journal of Hematology, to name just a few. Dr. Petz is a diplomate in internal medicine and subspecialty board diplomate in hematology. He has chaired and served on over twenty transfusion medicine and hematology committees, and received some of the highest honors in transfusion medicine, including the Emily Cooley Award, the and Morten Grove-Rasmussen Memorial Award and the Tibor Greenwalt Memorial Award and Lectureship from the American Association of Blood Banks (AABB); the Transfusion Medicine Academic Award from National Heart, Lung, and Blood Institute; and the Owen Thomas Award from the California Blood Bank Society. Dr. Petz chairs StemCyte's prestigious Medical Advisory Board.
Prof. Shinn-Zong Lin, M.D., Ph.D.
Chief Medical Officer, StemCyte Taiwan
Dr. Shinn-Zong (John) Lin is a Professor of Neurosurgery and Vice Superintendent of the Center of Neuropsychiatry at China Medical University Hospital in Taiwan. With an M.D. from National Defense Medical Center in Taipei, a Ph.D. in Physiology and Biophysics from State University of New York at Stony Brook and a Master's degree in Medical Management from Tulane University, he has served as a Professor of Neurosurgery at the National Defense Medical Center, Chairman of the Department of Neurosurgery at Tri-Service General Hospital, and a Professor of Neurosurgery and Chairman of NeuroMedical Scientific Center at Tzu-Chi General Hospital. He is the inventor of many patented treatment technologies for Brain Damage patients including the patentable technology entitled, "Treatment of Brain Damage using umbilical Cord Blood Cells". His background also includes: Membership of Editorial Boards Tzu-Chi Nursing Journal, Tzu-Chi Medical Journal, Formosan Journal of Surgery, Acta Neurologica Taiwanica, Surgical Neurology and Taiwan Neuroscience Alliance, Presidency of the International Neural Transplantation and Repair Meeting, Membership of 23 Professional Societies, 25 Distinguished Honors and Awards, 41 Research Programs, 3 Patents, 161 Publications in refereed journals, 25 Books and 178 Conference Papers and Invited Lectures. He is a highly accomplished neurosurgeon and applied neuroscientist for innovative therapies for stroke and neurodegenerative diseases. Dr. Lin is also a Member of the Advanced Therapeutics and Clinical Studies Committee
President, StemCyte Taiwan
Charles Lu has more than 13 years of experience in pharmaceutical business development and medical devices. Prior to joining StemCyte, Mr. Lu was the Chairman and General Manager of You An, a drugstore group in Taiwan, which he developed from three stores to 50 stores within three years. Previously, Mr. Lu was a senior marketing executive with Johnson & Johnson's Janssen Pharmaceutical unit. Mr. Lu received his M.B.A. from the University of Hartford Business School in Paris.
Chief Operating Officer, StemCyte India
He has attended Senior Cambridge from University of Cambridge, & then he graduated in Biology & Chemistry. Later he completed Diploma in Business Management (DBM) from Narsee Monjee (NMIMS) with major in International Marketing. He has over 35 years of expertise in Strategic Alliances, General Marketing & Sales for Medical industry touching different verticals such as: Pharmaceuticals, Medical Device & Diagnostics. He has worked in MNCs such as: Glaxo, Ranbaxy Labs & Boston Scientific Corporation. He has worked for 12 years for Bharat Serums & Vaccines and managed Exports. He has a vast experience of LATAM, CIS & SE Asian countries. Widely travelled to more than 35 countries. During his tenure with different companies, he attended training programs for Effective Field Management organized by OPPI, Learning International, UK on Total Quality management (TQM) & others in different countries: India, Singapore & USA.